A study reveals that continued intake of a superbug reduces symptoms of lactose intolerance

Almost 13 million people in Spain suffer from this dysfunction that causes abdominal pain, diarrhea, nausea, bloating and abdominal swelling.

A clinical study published by the Andalusian company Desarrollo deAlimentas Fermentados SL and the Quirón Salud Infanta Luisa Hospital in Seville highlights that daily intake of 10 milliliters of a synbiotic developed through a strain of lactobacillus DMG0017 reduces lactose intolerance in 70 percent of patients. The synbiotic, which goes on the market under the name Probimel, is a superbacteria capable of withstanding the acidity of the stomach and reaching the intestine alive, thus strengthening the immune system.

The trial was carried out with intolerant patients between 18 and 80 years old for six weeks and demonstrated a decrease in abdominal pain or dyspepsia, a decrease in episodes of diarrhea, nausea, flatulence and bloating, and a decrease in abdominal swelling. In Spain, nearly 13 million people suffer from lactose intolerance and the existing treatments, in addition to being expensive, are not covered by Social Security.

The study, carried out under the medical direction of Dr. Manuel Barrientos in order to see the clinical effectiveness of Probimel before its launch on the market, has shown that as the time of intake of this synbiotic increases, the symptoms improve significantly and Some patients even notice beneficial effects within two weeks, others take two months.

According to the publication, the live lactobacilli in Probimel contribute to improving lactose digestion. One of their properties is that they present lactase enzymatic activity, that is, they allow this enzyme to be synthesized thanks to their adaptive capacity.

One of the most important properties of the lactobacillus strain DMG0017 is that they are colonizers; That is, they generate their enzymatic activity by staying preferably in the upper intestinal part, significantly improving the correct functioning of the intestine, breaking down lactose and allowing its correct absorption permanently.

The researchers have highlighted that this represents "a great advance for those who suffer from this dysfunction, since, unlike other treatments based on the prior intake of enzymes before consuming foods containing lactose, Probimel naturally produces its own colony. that integrates into the microbiota and ensures that a daily dose is sufficient to be able to tolerate lactose throughout the day, making it very comfortable and efficient.